Trial Profile
A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Isatuximab (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 29 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 14 May 2021 Planned number of patients changed from 118 to 89.
- 18 Mar 2021 Results (n=33) assessing safety/tolerability, pharmacokinetics and preliminary efficacy of isatuximab in combination with carfilzomib in relapsed/refractory multiple myeloma, published in the Cancer